Aiming to Boost Molecular Dx Portfolio, Cepheid Acquires Assay Maker Sangtec | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
In an effort to expand its emerging molecular diagnostics business, Cepheid announced last week that it has acquired Sangtec Molecular Diagnostics from Altana Pharma for approximately $27 million in cash.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.